A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Destiny Pharma 25 Jan 2022

M3’s profile rising further

In a spree of positive updates to start 2022, Destiny Pharma begins the year with the profile of...

Read more
Eleco 25 Jan 2022

Time to buy the dip

Eleco is an IRP-rich firm that is trading at an unjustified discount to peers (2.4x fwd EV/sales vs...

Read more
Driver Group 24 Jan 2022

Reasons for optimism

Despite the delay, the results for the year to September were in-line with expectations at the adj....

Read more
Artisanal Spirits Company (The) 20 Jan 2022

Well positioned for strong sales growth in FY2022

ASC announced around 20% sales growth in a FY2021 trading update released today. Sales growth was...

Read more
Time Finance 20 Jan 2022

Early strategic progress not reflected in valuation

H1 ‘22 results (to 30 Nov ‘21) show steady progress on key metrics, with signs that Time’s refined...

Read more
Gattaca 18 Jan 2022

FY’22 NFI set to climb 7% as investment kicks in

Due to the latest Omicron outbreak, the pace of economic recovery has temporarily hit a soft patch....

Read more
Kromek Group 18 Jan 2022

Established leader in detection solutions

Kromek delivered a sound, well-managed, H1 performance given industry-wide supply chain and...

Read more
Polar Capital 13 Jan 2022

On track to meet full-year AUM forecast

AUM reached £24.3bn on 31 Dec 21, nine months into the financial year, up £3.4bn or 17% over the...

Read more
MPAC Group 12 Jan 2022

Trading update confirms a strong FY21

In a Trading Update for the year ended December 31st 2021 Mpac Group confirms strong performance...

Read more
Impax Asset Management 10 Jan 2022

Q1 AUM ahead of forecast

AUM grew by £4.1bn over Q1 of FY22 (1 Oct 21 – 30 Sep 22), reaching £41.4bn on 31 Dec 21, 11% up...

Read more
Begbies Traynor 10 Jan 2022

Bolt-on adds scale and profile to property services

BEG’s latest acquisition, chartered surveying firm Daniells Harrison, extends its geographical...

Read more
RUA Life Sciences 16 Dec 2021

Financials reflect increased investment

RUA Life Sciences interim results demonstrated the continued investment in the business and its new...

Read more
  • 1 of 57 pages

Register to be first

Get research on the companies that interest you straight to your inbox

Register For Updates